In the crowded field of stem cell research, most discussions revolve around mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells. But quietly, another lineage has been gaining serious scientific attention: Multilineage-differentiating Stress Enduring cells, or MUSE cells.
Originally identified within adult mesenchymal populations, MUSE cells are naturally occurring, pluripotent-like cells that can be harvested from accessible sources such as bone marrow, adipose tissue, and even peripheral blood.
Unlike embryonic stem cells or induced pluripotent stem cells, MUSE cells present a compelling clinical profile. They are consistently described as non-tumorigenic, unusually resilient under severe biological stress, and capable of integrating into damaged tissues with low immunogenicity. For regenerative physicians, this combination of safety, potency, and accessibility may represent a critical bridge between clinical feasibility and true multi-lineage regeneration.
The Discovery of MUSE Cells
The story of MUSE cells began in 2010, when a Japanese research group led by Dr. Mari Dezawa at Tohoku University was studying stress responses in mesenchymal stem cell cultures. When MSC cultures were exposed to extreme conditions such as prolonged serum deprivation, hypoxia, and mechanical stress, a small subpopulation not only survived but thrived. These stress-enduring survivors expressed Stage-Specific Embryonic Antigen-3 (SSEA-3), originated from adult tissue, and displayed pluripotent-like behavior without genetic reprogramming. This marked the identification of a biologically distinct and naturally occurring regenerative cell population.
Biological Identity and Unique Properties of MUSE Cells
MUSE cells possess a hybrid biological identity. They express pluripotency markers typically associated with embryonic or induced pluripotent cells, including SSEA-3, Nanog, Oct3/4, and Sox2. At the same time, they maintain mesenchymal lineage markers such as CD105, CD90, and CD73, confirming their MSC lineage origin. This dual phenotype appears to combine the safety profile and immunomodulatory behavior often associated with MSCs with the broader differentiation capacity characteristic of embryonic-like cells.
MUSE cells are rare in adult tissues. In bone marrow, they have been described as comprising approximately one to three percent of the MSC population. They appear at low frequency in adipose tissue and can be detected in peripheral blood in small quantities, particularly after injury. Their scarcity introduces translational challenges for harvesting and scale-up, but also supports the concept of MUSE cells as a biologically conserved regenerative reserve.
Pluripotency Without Tumorigenicity
Under appropriate cues, MUSE cells can differentiate into derivatives of all three germ layers. This includes ectodermal lineages such as neurons and glial cells, mesodermal lineages such as cardiomyocytes and osteocytes, and endodermal lineages such as hepatocytes and pancreatic beta cells. Unlike embryonic stem cells or iPSCs, MUSE cells have not been shown to form teratomas even after long-term culture or in vivo transplantation, making nontumorigenicity one of their most clinically significant differentiators.
Stress Endurance: The Defining Feature
Most mesenchymal stem cells undergo apoptosis under severe stress conditions. MUSE cells do not. They have been described as surviving oxidative stress, tolerating hypoxic environments such as ischemic tissue, maintaining telomere length, and exhibiting low senescence markers. This resilience makes them particularly suited for post-injury microenvironments where inflammation, nutrient scarcity, and oxidative stress typically compromise transplanted cells. Their stress-enduring phenotype is not incidental; it is the defining selection mechanism by which they are identified.
Homing Ability and Tissue Integration
One of the most compelling characteristics of MUSE cells is endogenous homing. They express chemokine receptors such as sphingosine-1-phosphate receptor 2 (S1PR2), allowing them to respond to gradients released by injured tissues. This supports the feasibility of systemic intravenous administration with migration to injury sites and reduced reliance on local injection. Once at the injury site, MUSE cells are described as differentiating into tissue-specific cell types, integrating into host architecture, secreting trophic factors, and modulating inflammation. Unlike traditional MSCs, whose effects are largely paracrine, MUSE cells appear to combine direct engraftment with signaling-based repair.
Preclinical Evidence Across Organ Systems
Preclinical research has reported MUSE cell activity across multiple organ systems. In neurological injury models, intravenously administered MUSE cells have been described as crossing the blood-brain barrier in stroke contexts, differentiating into mature neuronal phenotypes, improving motor function, and reducing infarct volume. In cardiac repair research, including porcine myocardial infarction models, systemic administration has been associated with engraftment into infarcted myocardium, expression of cardiac markers such as troponin-T, improved ejection fraction, reduced fibrosis, and enhanced angiogenesis. In hepatic injury models, MUSE cells have been described as differentiating into albumin-producing hepatocyte-like cells, integrating into hepatic cords, and normalizing liver enzymes. In dermatologic repair settings, they have been associated with accelerated epithelial closure, increased dermal thickness, and differentiation into keratinocytes and fibroblasts. Collectively, these findings suggest broad regenerative potential grounded in both differentiation and microenvironment modulation.
Early Human Clinical Applications
Although most data remain preclinical, early-phase human studies and compassionate-use reports have emerged. In acute myocardial infarction contexts, Phase I/II clinical research in Japan has described intravenous administration of allogeneic MUSE cells post-event with no infusion-related adverse events, improvements in left ventricular ejection fraction, and evidence consistent with reverse remodeling. In ischemic stroke, compassionate-use experiences have reported neurological improvement with MRI-confirmed migration into peri-infarct regions. In recessive dystrophic epidermolysis bullosa, intravenous infusion in pediatric patients has been associated with improved wound closure, reduced blistering frequency, and donor-derived keratinocyte integration. These findings provide early translational signals while underscoring the need for larger multicenter trials.
MUSE Cells in Regenerative Medicine
The appeal of MUSE cells lies in their convergence of pluripotency, safety, immunologic tolerance, homing ability, and systemic delivery feasibility. They may complement MSC-based therapies, exosome protocols, peptide signaling strategies, and gene-modified cellular platforms. Rather than representing a single-indication therapy, MUSE cells may function as a platform technology within regenerative medicine.
Challenges and Future Directions
Despite their promise, MUSE cell translation faces key hurdles. These include low frequency in adult tissues, scalability and GMP manufacturing demands, standardized SSEA-3 isolation methods, regulatory classification challenges, and production costs. International regulatory harmonization will be critical to broader clinical integration, and large multicenter randomized trials remain essential.
The Decade Ahead
The next decade will determine whether MUSE cells remain a scientific marvel or become a mainstay of clinical regenerative medicine. If their stress endurance, homing ability, safety profile, and differentiation capacity translate consistently into human therapeutic outcomes, MUSE cells may redefine how clinicians approach organ repair, degenerative disease, immune-mediated injury, and aging biology. At ISSCA, the conversation around MUSE cells is not about hype; it is about responsible evaluation, translational science, and clinical precision. Because sometimes, the most powerful cell is not the one engineered in the lab—it is the one nature kept in reserve.
